Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10750303 | 0.85 | PTPN1 (0.52) | ADRA2AADRA1AHPGDPARP1ALDH1A1 | |
| SCHEMBL398544 | 0.82 | ADRA2A (0.47) | ADRA2AADRA1AHPGDPARP1ALDH1A1 | |
| SCHEMBL11509515 | 0.82 | HTT (0.62) | HPGDPARP1ALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL8458647 | 0.82 | ADRA2A (0.57) | ADRA2AADRA1AHPGDPARP1LMNA | |
| SCHEMBL28182428 | 0.81 | HTR6 (0.65) | HPGDALDH1A1FABP4 | |
| SCHEMBL10131967 | 0.78 | NEK2 (0.43) | HPGDLMNASMN1; SMN2HTT | |
| SCHEMBL1879618 | 0.78 | ALDH1A1 (0.71) | HPGDALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL29280776 | 0.77 | ADRA2A (0.50) | ADRA2AADRA1AHPGDPARP1LMNA | |
| SCHEMBL10391003 | 0.77 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3554342 | 0.77 | LMNA (0.51) | ADRA2AADRA1AHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| CN-117813288-A | Arylamino derivative estrogen receptor modulator and use thereof | 西藏海思科制药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | ADRA2A 168/4885ADRA1A 112/4885HPGD 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.